AU2001259758A1 - Interleukin-1 inhibitors in the treatment of diseases - Google Patents

Interleukin-1 inhibitors in the treatment of diseases

Info

Publication number
AU2001259758A1
AU2001259758A1 AU2001259758A AU5975801A AU2001259758A1 AU 2001259758 A1 AU2001259758 A1 AU 2001259758A1 AU 2001259758 A AU2001259758 A AU 2001259758A AU 5975801 A AU5975801 A AU 5975801A AU 2001259758 A1 AU2001259758 A1 AU 2001259758A1
Authority
AU
Australia
Prior art keywords
interleukin
inhibitors
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259758A
Other languages
English (en)
Inventor
Timothy Connor
F. Ann Hayes
Larry F. O'neal
John E. Sims
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU2001259758A1 publication Critical patent/AU2001259758A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
AU2001259758A 2000-05-12 2001-05-11 Interleukin-1 inhibitors in the treatment of diseases Abandoned AU2001259758A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20388100P 2000-05-12 2000-05-12
US60/203,881 2000-05-12
US22242200P 2000-08-01 2000-08-01
US60/222,422 2000-08-01
PCT/US2001/015423 WO2001087328A2 (fr) 2000-05-12 2001-05-11 Inhibiteurs d"interleukine 1 dans le traitement de maladies

Publications (1)

Publication Number Publication Date
AU2001259758A1 true AU2001259758A1 (en) 2001-11-26

Family

ID=26898999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259758A Abandoned AU2001259758A1 (en) 2000-05-12 2001-05-11 Interleukin-1 inhibitors in the treatment of diseases

Country Status (4)

Country Link
US (3) US20010053764A1 (fr)
EP (4) EP1282435A2 (fr)
AU (1) AU2001259758A1 (fr)
WO (1) WO2001087328A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7811990B2 (en) * 1998-09-25 2010-10-12 Sciaticon Ab Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US7906481B2 (en) 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
IL143034A0 (en) 1998-11-13 2002-04-21 Immunex Corp Human tslp dna and polypeptides
US7288633B2 (en) 2001-07-23 2007-10-30 Immunex Corporation Modified human thymic stromal lymphopoietin
EP1450837A4 (fr) * 2001-08-07 2006-01-04 Immunex Corp Recepteurs de l'interleukine-1 dans le traitement de maladies
EP1471931A4 (fr) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst Export non traditionnel de cytokines pro-inflammatoires dependant du cuivre et methodes, compositions et kits associes
US20050159485A1 (en) * 2002-01-04 2005-07-21 Jost-Price Edward R. Combinations for the treatment of immunoinflammatory disorders and proliferative skin diseases
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
RU2325189C2 (ru) * 2003-03-20 2008-05-27 Фармация Корпорейшн Способ и фармацевтическая композиция для доставки противовоспалительного средства
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20050171015A1 (en) * 2003-10-31 2005-08-04 Crabtree Gerald R. Methods and agents for enhancing bone formation or preventing bone loss
DK1720893T3 (en) 2004-02-26 2014-11-24 Baylor Res Inst COMPOSITIONS AND PROCEDURES FOR THE SYSTEMIC TREATMENT OF ARTHRITIS
US7563804B1 (en) * 2004-04-19 2009-07-21 Hovanes John Ter-Zakarian FMF treatment
US7459426B2 (en) * 2004-06-04 2008-12-02 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005277236A1 (en) * 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
JP2008515896A (ja) * 2004-10-05 2008-05-15 オクスナー クリニック ファウンデーション Ｉｌ−１５によるｂ細胞増殖の増強
US20080292628A1 (en) * 2004-10-12 2008-11-27 Amprotein Corporation Chimeric Protein
WO2006076673A2 (fr) * 2005-01-14 2006-07-20 Regeneron Pharmaceuticals, Inc. Procede permettant de traiter l'obesite par une combinaison de therapies
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
WO2006124961A2 (fr) * 2005-05-16 2006-11-23 Children's Medical Center Corporation Methode de traitement de la lymphangioleiomyomatoses (lam)
SI2314623T1 (sl) * 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
JP2009512710A (ja) * 2005-10-21 2009-03-26 アムジエン・インコーポレーテツド Ｉｌ−１阻害剤を用いて血管石灰化を抑制する方法
EP3332807B1 (fr) 2005-10-26 2023-02-22 Novartis AG Utilisation d' anticorps anti il-1beta
AU2007333635B2 (en) 2006-12-20 2014-02-20 Xoma (Us) Llc Treatment of IL-1-beta related diseases
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
KR102606597B1 (ko) * 2007-05-29 2023-11-29 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
AU2008303955A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of Pseudomonas aeruginosa infection
KR20100061679A (ko) * 2007-09-11 2010-06-08 몬도바이오테크 래보래토리즈 아게 치료적 적용을 위한 티로트로핀 방출 호르몬
ATE553772T1 (de) * 2007-09-11 2012-05-15 Mondobiotech Lab Ag Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel
MX2010006823A (es) * 2007-12-20 2010-09-30 Xoma Technology Ltd Metodos para el tratamiento de la gota.
US20090191287A1 (en) * 2008-01-29 2009-07-30 Johnson W Dudley Mitigation of Inflammation-Related Injuries
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2293816B1 (fr) * 2008-06-06 2012-11-07 XOMA Technology Ltd. Procédés pour le traitement de la polyarthrite rhumatoïde
US20100069343A1 (en) * 2008-07-18 2010-03-18 Andrea Vambutus Methods of predicting steroid responsiveness with Il-1RII
CA2735939A1 (fr) 2008-09-05 2010-03-11 Xoma Technology Ltd. Procedes pour ameliorer la fonction des cellules beta
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
CN102573790B (zh) 2009-08-27 2017-03-22 拜欧米特生物制剂有限责任公司 用于产生白介素‑1受体拮抗剂的可植入装置
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
CA2773426A1 (fr) * 2009-09-10 2011-03-17 Cytos Biotechnology Ag Utilisation de conjugues de muteines d'interleukine-1 beta dans le traitement du diabete
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
US20130149312A1 (en) * 2010-04-16 2013-06-13 Mcmaster University Compositions and methods for treating copd exacerbation
NZ603191A (en) 2010-05-07 2015-02-27 Xoma Technology Ltd Methods for the treatment of il-1b related conditions
CN103221422B (zh) 2010-07-29 2017-03-29 十一生物治疗股份有限公司 嵌合il‑1受体i型激动剂和拮抗剂
MX2013002488A (es) 2010-09-03 2013-06-03 Biomet Biologics Llc Métodos y composiciones para suministrar un antagonista del receptor interleucina-1.
EP2968468B1 (fr) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Formulations de cytokine chimérique pour administration oculaire
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
WO2015081253A1 (fr) 2013-11-26 2015-06-04 Biomet Biologics, Llc Procédés de médiation des phénotypes macrophagiques
GB201412410D0 (en) * 2014-07-11 2014-08-27 Isis Innovation Treatment
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
CN114222587A (zh) * 2019-06-07 2022-03-22 塞阿克特免疫制药公司 下尿路慢性炎症的治疗和诊断

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5196430A (en) 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
USRE35450E (en) 1987-11-25 1997-02-11 Immunex Corporation Soluble human interleukin-1 receptors, compositions and method of use
US5296592A (en) * 1987-11-25 1994-03-22 Immunex Corporation Process for purifying interleukin-1 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
WO1989004838A1 (fr) * 1987-11-25 1989-06-01 Immunex Corporation Recepteurs d'interleukine-1
US5081228A (en) 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5064837A (en) * 1989-11-13 1991-11-12 Schering Corporation 3-substituted-1-aryl-2(h)-quinolones and their pharmaceutical compositions
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
WO1991015577A1 (fr) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
AU7683391A (en) 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
US5872095A (en) * 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
DE122008000051I1 (de) * 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
WO1992012724A1 (fr) * 1991-01-17 1992-08-06 The Upjohn Company Procede de prevention et de traitement du diabete sucre insulinodependant
JP3693671B2 (ja) 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
AU657701B2 (en) 1991-08-30 1995-03-23 Vertex Pharmaceuticals Incorporated Interleukin 1beta protease and interleukin 1beta protease inhibitors
US5770401A (en) * 1991-10-15 1998-06-23 Mullarkey; Michael F. Methods and compositions for treating allergic reactions
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
EP0547699A1 (fr) 1991-12-19 1993-06-23 Merck & Co. Inc. Dérivés peptidiques comme inhibiteurs d'enzyme convertissant l'interleukine 1-bêta
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
WO1993016710A1 (fr) 1992-02-21 1993-09-02 Merck & Co., Inc. DERIVES DE PEPTIDYLE UTILES COMME INHIBITEURS DE L'ENZYME CONVERTISSANT L'INTERLEUKINE-1$g(b)
US5547979A (en) 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
CA2118119C (fr) * 1992-04-30 2001-07-31 Robert C. Thompson Methodes de traitement des affections mediees par le facteur de necrose tumorale et l'interleukine-1
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
DE69408598T2 (de) 1993-06-08 1998-09-17 Vertex Pharmaceuticals Inc Cam Pyridazine als Interleukin-1-beta Verwandlungsenzym Inhibitoren
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
DK0822186T3 (da) 1994-01-20 2000-06-26 British Biotech Pharm L-tert-leucin-2-pyridylamid
NZ283876A (en) 1994-03-31 2001-03-30 Vertex Pharma Pyrimidinyl derivatives as interleukin inhibitors
US5519000A (en) 1994-04-01 1996-05-21 Centecor, Inc. Tumor necrosis factor inhibitors
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
WO1996000081A1 (fr) * 1994-06-24 1996-01-04 Immunex Corporation Compositions a base de polypeptides et a liberation lente, et procedes de traitement des affections intestinales inflammatoires
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
IT1269989B (it) 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5641751A (en) 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
US5753628A (en) 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
CZ299025B6 (cs) * 1996-02-09 2008-04-02 Amgen Inc. Farmaceutická kompozice a její použití
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
EP0886525A1 (fr) * 1996-03-15 1998-12-30 The General Hospital Corporation MORT CELLULAIRE PROGRAMMEE ET INTERLEUKINE-1$g(b)
US5874592A (en) * 1996-04-03 1999-02-23 Kyowa Hakko Kogyo Co., Ltd. Physiologically active substance EI-2128-1
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
AU722662B2 (en) 1996-05-20 2000-08-10 Darwin Discovery Limited Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors
EP0818439B1 (fr) * 1996-07-02 1999-10-13 Nisshin Flour Milling Co., Ltd. Dérivés d'imides
US6054559A (en) * 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US5883131A (en) 1997-07-09 1999-03-16 Pfizer Inc. Cyclic sulfone derivatives
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
JP2001517666A (ja) 1997-09-23 2001-10-09 藤沢薬品工業株式会社 チアゾール誘導体
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6306978B1 (en) * 1999-02-05 2001-10-23 General Electric Company Capping of polyphenylene ether resin
US6086095A (en) 1999-07-30 2000-07-11 Milliken & Company Airbag cushion exhibiting low seam and fabric usage and simultaneously high available inflation volume
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes

Also Published As

Publication number Publication date
US20090022733A1 (en) 2009-01-22
EP2329842A3 (fr) 2011-07-27
EP1282435A2 (fr) 2003-02-12
US20040023869A1 (en) 2004-02-05
EP1712239A2 (fr) 2006-10-18
US20010053764A1 (en) 2001-12-20
WO2001087328A2 (fr) 2001-11-22
WO2001087328A3 (fr) 2002-08-22
EP1712239A3 (fr) 2007-08-22
EP2241328A1 (fr) 2010-10-20
EP2329842A2 (fr) 2011-06-08

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
PL374118A1 (en) Interleukin-1 receptors in the treatment of diseases
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU2002326600A1 (en) Side-exit catheter and method for its use
AU2002358270A1 (en) Zero-order sustained released dosage forms and method of making the same
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AUPR074500A0 (en) Treatment of t cell disorders
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001292019A1 (en) Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU2001260834A1 (en) The treatment of herpes
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases